HC Wainwright Has Positive View of Vor Biopharma Q4 Earnings

Vor Biopharma Inc. (NASDAQ:VOR) – Investment analysts at HC Wainwright lifted their Q4 2026 EPS estimates for shares of Vor Biopharma in a report issued on Monday, November 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.83) per share for the quarter, up from their previous estimate of ($0.94). The consensus estimate for Vor Biopharma’s current full-year earnings is ($2.56) per share. HC Wainwright also issued estimates for Vor Biopharma’s Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.86) EPS, Q3 2027 earnings at ($0.78) EPS, Q4 2027 earnings at ($0.79) EPS, FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($2.10) EPS, FY2029 earnings at $1.50 EPS and FY2030 earnings at $3.90 EPS.

A number of other brokerages also recently commented on VOR. Stifel Nicolaus set a $40.00 price objective on shares of Vor Biopharma in a research report on Monday. Citigroup raised shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, October 15th. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday. William Blair assumed coverage on Vor Biopharma in a report on Wednesday, October 21st. They set an “outperform” rating for the company. Finally, Wedbush boosted their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.29.

Vor Biopharma Stock Up 3.2%

NASDAQ VOR opened at $19.86 on Wednesday. The firm’s fifty day moving average price is $20.61 and its two-hundred day moving average price is $17.39. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $26.00.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Friday, October 30th. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VOR. Braidwell LP boosted its position in shares of Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after acquiring an additional 106,330 shares during the period. Renaissance Technologies LLC bought a new position in Vor Biopharma during the first quarter worth about $2,298,000. Bank of America Corp DE increased its position in Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after acquiring an additional 112,496 shares during the period. Bank of New York Mellon Corp acquired a new stake in Vor Biopharma in the 2nd quarter worth about $1,799,000. Finally, Alps Advisors Inc. raised its stake in Vor Biopharma by 42.5% in the 3rd quarter. Alps Advisors Inc. now owns 78,371 shares of the company’s stock worth $1,495,000 after purchasing an additional 23,373 shares in the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.